about
CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic VirusesPoxvirus tropismOncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesPreventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase geneMyxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.Preferential replication of vaccinia virus in the ovaries is independent of immune regulation through IL-10 and TGF-βEfficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system.Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.Therapeutic Vaccine Strategies against Human Papillomavirus.A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9.Immunotherapy for pancreatic cancer - science driving clinical progress.Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications.JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase.Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancerInvestigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study.Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors.Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus.
P2860
Q26766798-EB267FCD-60A5-435B-AAA5-BD6F55DB301CQ28237434-9BB90591-D32A-40D9-9D9E-5863B9BF7754Q33924550-2C217474-046D-4A39-9056-597E440DAFA3Q34235915-32E613DF-1DB7-4A72-BBB5-9DFE40AE8310Q34287746-5594581B-B888-4EA5-872F-09462C2A7E9AQ35223458-6FD2401D-E505-4081-AD45-C491E3B7793AQ35292546-79A2BB66-D423-4C50-AC90-0A7570D87532Q35488657-282643C1-26DF-4B74-A2CC-5FD9EDD07FB6Q35635226-B3196527-C3E2-4AC0-BC55-86FA6D44B2E8Q35783456-C89EBADD-4116-47D2-83BD-79509643030FQ35826752-3D794EF8-E67C-485D-99B1-0DA40350A61EQ36064702-4C28E9DC-7547-4E3E-98AC-2D33EF79DB16Q36133140-2857C26E-40C3-4836-AEDA-459255EE2077Q36377208-13D8A29C-9848-4A36-B413-E956D491FB49Q36909702-8CE5E731-B85E-4C17-B11B-EBF7ECD00B17Q36922264-E3691502-68A7-491F-AA19-DAAB7DE60ABAQ37389574-D2B35E88-C62D-4A92-899F-3CF038AF3CAAQ39292187-77F0199F-4C9E-49B0-94F6-442FC8F8E7A1Q39556062-1C0695B2-3962-4FC6-B473-6550F0C29544Q40176322-7AD106F6-331A-4D9A-90A1-602E04618C60Q40452852-A045F08B-C7FF-4791-822A-E6B56BBB7003Q45325487-0902A9FB-B9FE-40E3-96DD-845000825432
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Vaccinia as a vector for gene delivery.
@ast
Vaccinia as a vector for gene delivery.
@en
type
label
Vaccinia as a vector for gene delivery.
@ast
Vaccinia as a vector for gene delivery.
@en
prefLabel
Vaccinia as a vector for gene delivery.
@ast
Vaccinia as a vector for gene delivery.
@en
P2860
P356
P1476
Vaccinia as a vector for gene delivery.
@en
P2093
David L Bartlett
Z Sheng Guo
P2860
P304
P356
10.1517/14712598.4.6.901
P407
P577
2004-06-01T00:00:00Z